{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:01Z","timestamp":1786979941843,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,10]],"date-time":"2015-05-10T00:00:00Z","timestamp":1431216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00280-015-2746-3","type":"journal-article","created":{"date-parts":[[2015,5,9]],"date-time":"2015-05-09T03:37:34Z","timestamp":1431142654000},"page":"47-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients"],"prefix":"10.1007","volume":"76","author":[{"given":"Maurice C.","family":"van Staveren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans","family":"Opdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 B. P.","family":"van Kuilenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Gerard","family":"Maring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,10]]},"reference":[{"issue":"2","key":"2746_CR1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","volume":"249","author":"M Boisdron-Celle","year":"2007","unstructured":"Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, Gamelin E (2007) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249(2):271\u2013282","journal-title":"Cancer Lett"},{"issue":"9","key":"2746_CR2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1023\/A:1012294617392","volume":"12","author":"PA Di","year":"2001","unstructured":"Di PA, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G, Allegrini G, Mini E, Bocci G, Conte PF, Del TM (2001) Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 12(9):1301\u20131306","journal-title":"Ann Oncol"},{"issue":"10","key":"2746_CR3","first-page":"2672","volume":"5","author":"RB Diasio","year":"1999","unstructured":"Diasio RB, Johnson MR (1999) Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 5(10):2672\u20132673","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2746_CR4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00280-005-0139-8","volume":"58","author":"J Ciccolini","year":"2006","unstructured":"Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer JC, Richard K, Dales JP, Durand A, Milano G, Seitz JF, Lacarelle B (2006) Toxic death-case after capecitabine\u00a0+\u00a0oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol 58(2):272\u2013275","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"2746_CR5","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","volume":"12","author":"MC Etienne","year":"1994","unstructured":"Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12(11):2248\u20132253","journal-title":"J Clin Oncol"},{"issue":"5","key":"2746_CR6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/tpj.2013.25","volume":"13","author":"MC Staveren van","year":"2013","unstructured":"van Staveren MC, Jan GH, van Kuilenburg AB, Gelderblom H, Maring JG (2013) Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J 13(5):389\u2013395","journal-title":"Pharmacogenomics J"},{"issue":"Pt 1","key":"2746_CR7","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1042\/bj20031463","volume":"379","author":"AB Kuilenburg Van","year":"2004","unstructured":"Van Kuilenburg AB, Stroomer AE, Van Lenthe H, Abeling NG, Van Gennip AH (2004) New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid? Biochem J 379(Pt 1):119\u2013124. doi: 10.1042\/BJ20031463","journal-title":"Biochem J"},{"issue":"6","key":"2746_CR8","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00280-011-1661-5","volume":"68","author":"MC Staveren van","year":"2011","unstructured":"van Staveren MC, Theeuwes-Oonk B, Guchelaar HJ, van Kuilenburg AB, Maring JG (2011) Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother Pharmacol 68(6):1611\u20131617","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2746_CR9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","volume":"16","author":"RB Diasio","year":"1989","unstructured":"Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16(4):215\u2013237","journal-title":"Clin Pharmacokinet"},{"issue":"9\u201311","key":"2746_CR10","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/15257770600894576","volume":"25","author":"AB Kuilenburg van","year":"2006","unstructured":"van Kuilenburg AB, van Lenthe H, Van Gennip AH (2006) Activity of pyrimidine degradation enzymes in normal tissues. Nucleosides Nucleotides Nucleic Acids 25(9\u201311):1211\u20131214","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"2","key":"2746_CR11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1665-2681(19)31651-5","volume":"9","author":"G Ramadori","year":"2010","unstructured":"Ramadori G, Cameron S (2010) Effects of systemic chemotherapy on the liver. Ann Hepatol 9(2):133\u2013143","journal-title":"Ann Hepatol"},{"issue":"4","key":"2746_CR12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/clpt.2014.143","volume":"96","author":"RD Harvey","year":"2014","unstructured":"Harvey RD, Morgan ET (2014) Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents. Clin Pharmacol Ther 96(4):449\u2013457. doi: 10.1038\/clpt.2014.143","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2746_CR13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1365-2125.2000.00189.x","volume":"49","author":"ML Williams","year":"2000","unstructured":"Williams ML, Bhargava P, Cherrouk I, Marshall JL, Flockhart DA, Wainer IW (2000) A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. Br J Clin Pharmacol 49(5):485\u2013488","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2746_CR14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.10599","volume":"101","author":"AB Kuilenburg van","year":"2002","unstructured":"van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH (2002) Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 101(3):253\u2013258","journal-title":"Int J Cancer"},{"issue":"2","key":"2746_CR15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejca.2006.09.017","volume":"43","author":"AB Kuilenburg van","year":"2007","unstructured":"van Kuilenburg AB, Klumpen HJ, Westermann AM, Zoetekouw L, van Lenthe H, Bakker PJ, Richel DJ, Guchelaar HJ (2007) Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. Eur J Cancer 43(2):459\u2013465","journal-title":"Eur J Cancer"},{"issue":"1","key":"2746_CR16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00007691-200502000-00006","volume":"27","author":"JG Maring","year":"2005","unstructured":"Maring JG, Schouten L, Greijdanus B, de Vries EGE, Uges DR (2005) A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5,6-dihydrofluorouracil in plasma. Ther Drug Monit 27(1):25\u201330","journal-title":"Ther Drug Monit"},{"issue":"3","key":"2746_CR17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03257473","volume":"51","author":"AB Kuilenburg van","year":"2012","unstructured":"van Kuilenburg AB, Hausler P, Schalhorn A, Tanck MW, Proost JH, Terborg C, Behnke D, Schwabe W, Jabschinsky K, Maring JG (2012) Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 51(3):163\u2013174","journal-title":"Clin Pharmacokinet"},{"issue":"22","key":"2746_CR18","first-page":"5433","volume":"53","author":"Z Lu","year":"1993","unstructured":"Lu Z, Zhang R, Diasio RB (1993) Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53(22):5433\u20135438","journal-title":"Cancer Res"},{"issue":"5","key":"2746_CR19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/0009-9236(95)90171-X","volume":"58","author":"Z Lu","year":"1995","unstructured":"Lu Z, Zhang R, Diasio RB (1995) Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 58(5):512\u2013522. doi: 10.1016\/0009-9236(95)90171-X","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2746_CR20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2125.1996.34212.x","volume":"41","author":"J McMurrough","year":"1996","unstructured":"McMurrough J, McLeod HL (1996) Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 41(5):425\u2013427","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2746_CR21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2125.1998.00751.x","volume":"46","author":"SA Ridge","year":"1998","unstructured":"Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, van Kuilenburg AB, van Gennip AH, McLeod HL (1998) Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol 46(2):151\u2013156","journal-title":"Br J Clin Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2746-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2746-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2746-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T17:34:01Z","timestamp":1566668041000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2746-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,10]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["2746"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2746-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,10]]}}}